MENLO PARK, Calif., July 13, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), is pleased to announce that the company's chief executive officer and its president are invited by the New York Stock Exchange (NYSE) to ring the NYSE Opening Bell® on Wednesday, July 15, 2015 to celebrate its listing. Its stock was uplisted and commenced trading on June 25, 2015.
"BioPharmX is proud to ring the opening bell on behalf of our employees, investors and other supporters. We found that the NYSE MKT, the premier U.S. equities market for listing and trading early stage companies, is committed to providing a strong platform for growth," said Jim Pekarsky, chief executive officer of BioPharmX Corporation. "We look forward to the great exposure the NYSE MKT will give us to a larger group of investors while increasing awareness of our pipeline of products being developed to address significant, unmet medical needs."
Jim Pekarsky and BioPharmX President, Anja Krammer, will both be present for this important ceremony.
NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.
The NYSE Opening Bell will ring at 9:30 a.m. EDT and can be viewed live on the NYSE website at https://nyse.nyx.com/the-bell/todays-bells-live. Photos and video of the NYSE Bell Ringing Ceremony will also be available, courtesy of the NYSE, on Facebook (NYSE), Twitter (@NYSE and @NYSECam), and Livestream.
About BioPharmX Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including women's health and dermatology. To learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements." These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX is a pending trademark of BioPharmX Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.
Logo - http://photos.prnewswire.com/prnh/20150711/235327LOGO
SOURCE BioPharmX Corporation
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article